News Releases

SEATTLE --(BUSINESS WIRE)--Aug. 8, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today reported the grant of an equity inducement award to Mark Litton ,

SEATTLE--( BUSINESS WIRE )--Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at the 2018

SEATTLE --(BUSINESS WIRE)--Aug. 6, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will present a business overview and update at

SEATTLE --(BUSINESS WIRE)--Aug. 6, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative immunotherapies to treat cancer, autoimmune/inflammatory and other diseases, today announced the appointment of life sciences veteran Mark Litton , Ph.D.

SEATTLE & HANGZHOU, China --(BUSINESS WIRE)--Jul. 20, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital , a life

SEATTLE --(BUSINESS WIRE)--May 22, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, today announced the company will

SEATTLE --(BUSINESS WIRE)--May 14, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory, and other diseases, provided a corporate update and

SEATTLE --(BUSINESS WIRE)--Apr. 24, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN) announced today the appointment of Chris Peetz to its Board of Directors. Mr. Peetz, an experienced life sciences executive, currently serves as the Chief Executive Officer of Flashlight Therapeutics.

-- ALPN-202 is a potential novel immuno-oncology therapy providing dual PD-L1/CTLA-4 antagonism with CD28 costimulation -- -- Unique mechanism seeks to address lack of costimulatory activity of existing immuno-oncology therapies -- -- Data Presented at 2018 American Association for Cancer Research

New preclinical data on ALPN-202 program to be presented at 2018 American Association for Cancer Research Annual Meeting SEATTLE --(BUSINESS WIRE)--Mar. 28, 2018-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies